8-K: Intelligent Bio Solutions Reports Share Count Update

Intelligent Bio Solutions Inc. announced an updated total of 3,018,188 outstanding common shares as of July 31, 2026, resulting from recent stock sales, warrant exercises, and advisory agreements.

Summary

• Intelligent Bio Solutions Inc. (the Company) reported that as of the close of business on July 31, 2026, the total number of outstanding shares of its common stock was 3,018,188.
• This increase in outstanding shares is attributed to three primary activities:
• 1. The sale of common stock under an At The Market Offering Agreement dated September 18, 2024.
• 2. The exercise of previously disclosed outstanding warrants.
• 3. The issuance of restricted common stock under an Investor Relations and Corporate Development Advisory Agreement dated February 29, 2024.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development, primarily due to the increase in outstanding shares without immediate indication of significant operational progress.

Positives

• The company is actively engaging in capital-raising activities through an At The Market offering, which can provide ongoing funding.
• The exercise of warrants indicates that warrant holders see value in the company's stock, potentially signaling confidence.
• The issuance of shares for advisory services suggests the company is leveraging external expertise for growth and investor relations.

Negatives

• The total number of outstanding shares has increased, which can lead to dilution for existing shareholders if not accompanied by proportional growth in company value.
• The filing does not provide details on the net proceeds from the ATM offering or warrant exercises, making it difficult to assess the financial benefit.

Risks

• Potential for further share price dilution if the capital raised does not translate into significant business growth or profitability.
• The reliance on advisory agreements for corporate development and investor relations may indicate a need for external support in these areas.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future financial performance. It solely reports on the current number of outstanding shares.

Management Comments

• The total number of outstanding shares of the Company's common stock as of the close of business on July 31, 2026, is 3,018,188.

Industry Context

StockSavvy.ai notes that companies in the biotechnology and life sciences sector often utilize At The Market offerings and warrant exercises to fund ongoing research, development, and clinical trials. The issuance of shares for advisory services is also a common practice for companies seeking strategic guidance and market access.

Stakeholder Impact

• Existing shareholders may experience dilution in their ownership percentage due to the increase in the total number of outstanding shares.
• Potential investors will note the increased share count, which may influence their valuation models.

Key Dates

Keywords

share count, outstanding shares, common stock, At The Market offering, warrant exercise, restricted stock, capital raise, shareholder dilution